You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

Hepatitis C FDA-Approved
Combination Therapy


  Boceprevir + Pegylated Interferon + Ribavirin
  Telaprevir+ Pegylated Interferon + Ribavirin
  Pegasys + Copegus (peginterferon alfa-2a + ribavirin)
  PegIntron + Rebetol (peginterferon alfa-2b + ribavirin)
  Roferon A + Ribavirin (Standard interferon alfa-2a + ribavirin)
  Intron A + Rebetol (Standard Interferon alfa-2b + ribavirin)
  Infergen + Ribavirin (consensus Interferon + ribavirin)


Boceprevir + Pegylated Interferon + Ribavirin

Articles on Boceprevir + Pegylated Interferon + Ribavirin

Boceprevir Patient Assistance Programs
5-31-2011

Boceprevir (Victrelis) Approved for Hepatitis C

5-17-2011

Boceprevir for HCV Wins Unanimous FDA Committee Recommendation
4-29-2011

FDA Hearings Next Week on Boceprevir and Telaprevir for HCV
4-23-2011

Boceprevir Improves Response to Interferon-Based HCV Therapy

4-1-2011

FDA Committee Sets Review Dates for HCV Drugs Boceprevir and Telaprevir
3-18-2011

HCV Protease Inhibitor Boceprevir Improves Response for Treatment-Naive and Non-responders
3-15-2011

HCV Protease Inhibitor Boceprevir Accepted for Priority Review in U.S. and Europe
1-14-2010

Boceprevir Improves Response to Interferon-based Therapy and Allows Many Patients to Reduce Duration
11/02/2010


HCV RESPOND-2 Final Results High Sustained Virologic Response Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin when Re- Treated with Boceprevir Plus PEGINTRON (Peginterferon alfa-2b)/Ribavirin
11/02/2010

Boceprevir Combined with Peginterferon alfa-2b/Ribavirin for Treatment-Naïve Patients with HCV Genotype 1
11/02/2010

HCV Protease Inhibitor Boceprevir Increased Sustained Response to Interferon-based Therapy in Phase 3 Studies
8/06/2010


Telaprevir + Pegylated Interferon + Ribavirin

Articles on Telaprevir + Pegylated Interferon + Ribavirin

Telaprevir Improves Hepatitis C Treatment Response
6-28-2011

Telaprevir Patient Assistance Programs
5-31-2011

Telaprevir (Incivek) Approved for Hepatitis C
5-24-2011

FDA Committee Unanimously Recommends Telaprevir
5-03-2011

FDA Hearings Next Week on Boceprevir and Telaprevir for HCV
4-23-2011

Telaprevir Improves HCV Cure Rates Regardless of IL28B Status
4-5-2011

Telaprevir Combo Works for HCV Patients with Prior Unsuccessful Treatment
4-1-2011

FDA Committee Sets Review Dates for HCV Drugs Boceprevir and Telaprevir
3-18-2011

HCV Protease Inhibitor Telaprevir Will Get Priority Review in U.S. and Canada
1-25-2011

Vertex Completes FDA Submission of Telaprevir New Drug Application
11/30/2010

Direct-acting Drug Combos Suppress HCV without Interferon, but Resistance Remains a Concern
11/15/2010

Telaprevir Increases Sustained Response Rates and Shortens Treatment Duration for Newly Treated Hepatitis C Patients
11/02/2010


Vertex Begins Trial of Telaprevir for Treatment-naive Chronic Hepatitis C Patients
10/29/2010


Telaprevir Combination Therapy Boosts Sustained Response Rates for Previously Treated Hepatitis C Patients
9/10/2010



Pegasys + Copegus
peginterferon alfa-2a + Copegus (ribavirin)

PEGASYS Medication Guide
Pegasys Product Information
Copegus Medication Guide
Copegus Product Information

Articles on Pegasys + Copegus

Longer Interferon Treatment Raises Hepatitis C Cure Rate
5-10-2011

Treatment of Recurrent Hepatitis C after Liver Transplantation
2-18-2011

Genentech Warns of Infection Risk from Alcohol Pads Packaged with Fuzeon and Pegasys
1-18-2011


Anemia during Hepatitis C Treatment Predicts Sustained Response to Pegylated Interferon/ribavirin
1-11-2011


Pre-treatment with Ribavirin Improves Response to Interferon-based Therapy for Hepatitis C

12/14/2010

Menopause and Obesity Linked to HCV Relapse after Interferon-based Treatment
12/10/2010

Drinking More Coffee Linked to Improved Response to Hepatitis C Treatment
12/03/2010

Can Chronic Hepatitis C Patients with
Genotypes 2 or 3 Benefit from Shorter Interferon Treatment?
10/26/2010


Week 4 Rapid Virological Response Predicts Sustained Response to Interferon-based Hepatitis C Treatment
9-03-2010

Pegylated Interferon plus Ribavirin Has High Sustained Response Rates in Children with Hepatitis C
8-31-2010

Asian Patients Respond as Well as Whites to Interferon-based Therapy for Chronic Hepatitis C
7-13-2010

Immune Cells Show Signs of Senescence after Liver Transplantation
7-09-2010

Response at Week 8 Accurately Predicts Sustained Response to Pegylated Interferon plus Ribavirin for Hepatitis C
7-05-2010

Blood-boosting Adjuvant Therapies Can Improve Response to Interferon-based Treatment for Hepatitis C
6-25-2010

Sustained Virological Response at 12 Weeks Post-treatment May be as Good as 24 Weeks for Determining Interferon Cure
6-11-2010

Nitazoxanide Increases Response to Pegylated Interferon plus Ribavirin in Treatment-naive and Non-responder Hepatitis C Patients
5-28-2010

Pegylated Interferon plus Ribavirin Works as Well in HIV/HCV Coinfected Patients with Cirrhosis
5-28-2010

HCV NS5A Inhibitor BMS-790052 Suppresses Viral Replication in Combination with Pegylated Interferon/ribavirin
4-30-2010

Closely Individualized Treatment with Pegylated Interferon plus Ribavirin Is Possible Based on Baseline Viral Load and Early Response
4-23-2010

Predictors of Rapid and Early Virological Response to Pegylated Interferon plus Ribavirin in Genotype 1 Hepatitis C Patients
4-9-2010

Is One Type of Pegylated Interferon More Effective for Treating Chronic Hepatitis C?
2-12-2010

Influence of HCV Subtype and Quasispecies on Virological Response to Interferon-Based Therapy
1-12-2010

Management of Non-responders and Relapsers Treated with Pegylated Interferon plus Ribavirin for Chronic Hepatitis C
1-5-2010

Low-dose Pegylated Interferon Maintenance Therapy Does Not Reduce Clinical Outcomes despite Persistent HCV Suppression
1-5-2010

HCV Viral Load Decline during First 48 Hours of Pegylated Interferon plus Ribavirin in HCV Monoinfected and HCV/HIV Coinfected Patients
12/04/09

Hepatitis C Treatment Appears to Be Declining; People with Hard-to Treat Genotypes Are Half as Likely to Receive Therapy
12/01/09

Genotype 1 Chronic Hepatitis C Patients with Low Viral Load Can Achieve Sustained Response with 24 Weeks of Pegylated Interferon plus Ribavirin
11/17/09

Pegylated Interferon plus Ribavirin Can Effectively Treat both Hepatitis B and C In Dually Infected Patients
11/17/09

Reducing Ribavirin Dose Raises Relapse Risk for Chronic Hepatitis C Patients, but
Pegylated Interferon May be Decreased after Week 12
10-16-2009

Advocates Urge Consideration of Hepatitis C Treatment for Active Injection Drug Users
8-14-2009

Pegasys
and PegIntron for Chronic Hepatitis C Perform Similarly in IDEAL Study
7-28-2009

Detectable HCV RNA at Week 8 Is Best Predictor of Relapse in Genotype 1 Hepatitis C Patients Treated with Pegylated Interferon plus Ribavirin
6-23-2009

Effectiveness of Pegylated Interferon plus Ribavirin for Chronic Hepatitis C Patients with HCV Genotypes 5 or 6
6-19-2009

IDEAL Study Shows that Greater Hemoglobin Decline during Treatment with Pegylated Interferon plus Ribavirin Is Associated with Better Response
5/22/09

Extended 72-week Treatment with Pegylated Interferon plus Ribavirin Did Not Improve Outcomes among Slow Responder Hepatitis C Patients
5/08/09

Early Treatment of Acute Hepatitis C with Pegylated Interferon Monotherapy Produces Better Results than Delayed Combination Therapy
5/05/09


Adding Telaprevir Improves Sustained Response to Pegylated Interferon plus Ribavirin in Genotype 1 Chronic Hepatitis C Patients (PROVE3)
5/05/09


Experimental HCV Protease Inhibitor SCH 900518, with or without Pegylated Interferon, Appears Safe and Exhibits Good Antiviral Activity
5/05/09


HIV Positive and Negative Individuals with Acute or Early Chronic Hepatitis C Respond Well to 24 Weeks of Pegylated Interferon plus Ribavirin
4/10/09


Pegylated Interferon alfa-2a (Pegasys) Relapse Rates in Genotype 1 Chronic Hepatitis C Patients Depend on Weight-based Ribavirin Dosage
4/07/09


Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C
4/03/09


Phase 1 OPTIMA Trial Finds Controlled-release Nitazoxanide Improves Response to Pegylated Interferon plus Ribavirin
2/27/2009


Extended Pegylated Interferon plus Ribavirin Therapy Improves Sustained Response Rate in Slow Responder Genotype 1b Hepatitis C Patients
2/03/2009


Adherence to Pegylated Interferon/ribavirin Therapy for Hepatitis C and Early Treatment Response
1/30/2009


Combination of Virus and Host Factors Predict Virological Response to Pegylated Interferon plus Ribavirin for Chronic Hepatitis C
1/27/2009


SAMe Improves Early Response to Pegylated Interferon/ribavirin in Small Study
12/12/2008


Long-term Low-dose Pegylated Interferon May Improve Liver Inflammation and Fibrosis in a Select Subgroup of Prior Non-responders
12/08/2008


Results of the IDEAL Study of Treatment of African Americans with Chronic Hepatitis C: A Slide Set Review
12/082008


Nitazoxanide Enhances Anti-HCV Activity of Pegylated interferon/ribavirin and STAT-C Agents
12/02/2008


Nitazoxanide Enhances Anti-HCV Activity of Pegylated interferon/ribavirin and STAT-C Agents
12/02/2008


Extended Duration Pegylated Interferon/ribavirin for Prior Non-responders and Relapsers
11/25/2008


Canadian POWeR Study Finds Patients with Advanced Liver Disease Respond Poorly to Pegylated Interferon plus Ribavirin
11/21/2008


Genotype 1 HCV Patients with Early but Not Rapid Response May Benefit from 72 Weeks of Pegylated Interferon plus Ribavirin
11/18/2008


IDEAL Researchers Look at Predictors of Response to Pegylated Interferon plus Ribavirin, including Race/ethnicity and Anemia
11/07/2008


Extended Duration Pegylated Interferon/ribavirin for Prior Non-responders and Relapsers
11/25/2008


IDEAL Researchers Look at Predictors of Response to Pegylated Interferon plus Ribavirin, including Race/ethnicity and Anemia
11/07/2008


Safety and antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in treatment-na´ve patients with chronic hepatitis C genotype 1 infection given as monotherapy and in combination with peginterferon alfa-2a (P) and ribavirin (R)
11/05/2008


Safety and antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in combination therapy with peginterferon alfa-2a (P) and ribavirin (R) for 28 days in P+R treatment-experienced patients with chronic hepatitis C genotype 1 infection
11/05/2008


Hematologic Safety Data From the IDEAL Trial: Neutropenia, Anemia, and Thrombocytopenia Profiles of Peginterferon alfa/Ribavirin
11/05/2008


Treatment-Related Anemia Is Associated With Higher SVR Rates Among Persons Treated With Peginterferon (PEG)/Ribavirin (RBV): Results From the IDEAL Study
11/05/2008


Response to Pegylated Interferon plus Ribavirin in Asian Patients with Genotype 1 Chronic Hepatitis C
10/21/2008





PegIntron + Rebetol
peginterferon alfa-2b + Rebetol (ribavirin)

PEG-INTRON« Prescribing Information
REBETOL« Prescribing Information

Articles on PegIntron + Rebetol

Longer Interferon Treatment Raises Hepatitis C Cure Rate
5-10-2011

Treatment of Recurrent Hepatitis C after Liver Transplantation
2-18-2011


Pre-treatment with Ribavirin Improves Response to Interferon-based Therapy for Hepatitis C

12/14/2010


Menopause and Obesity Linked to HCV Relapse after Interferon-based Treatment
12/10/2010


Drinking More Coffee Linked to Improved Response to Hepatitis C Treatment
12/03/2010

HCV RESPOND-2 Final Results High Sustained Virologic Response Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin when Re- Treated with
Boceprevir Plus PEGINTRON (Peginterferon alfa-2b)/Ribavirin
11/09/2010

Boceprevir Combined with Peginterferon alfa-2b/Ribavirin for Treatment-Naïve Patients with HCV Genotype 1
11/09/2010

Frequencies of Resistance-Associated Amino Acid Variants Following Combination Treatment with
Boceprevir Plus PEGINTRON (PegInterferon Alfa-2b)/Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 1 (G1)
11/09/2010

Response-Guided Therapy with
Boceprevir + Peginterferon alfa-2b/Ribavirin for Treatment-Naïve Patients with Hepatitis C Virus Genotype 1 Was Similar to a 48-Wk Fixed-Duration Regimen with Boceprevir + Peginterferon alfa-2b/Ribavirin in SPRINT-2
11/09/2010

Virological response and safety of 4 weeks’ treatment with the
protease inhibitor BI 201335 combined with 48 weeks of peginterferon alfa 2a and ribavirin for treatment of HCV GT-1 patients who failed peginterferon/ribavirin
11/09/2010

Combination Therapy With
BMS-790052 and BMS-650032 Alone or With Pegylated Interferon and Ribavirin (pegIFN/RBV) Results in Undetectable HCV RNA Through 12 Weeks of Therapy in HCV Genotype 1 Null Responders
11/09/2010

High Correlation Between Week 4 and Week 12 as the Definition for Null Response to Peginterferon alfa (PEG) Plus Ribavirin (R) Therapy: Results From the IDEAL Trial
11/09/2010

Impact of PegIntron (PEG) Maintenance Therapy (MT) on Fibrosis Biomarkers (FibroTest [FT]/FibroSURE) in Prior Nonresponders With METAVIR Fibrosis Scores (MFS) of F2/F3: Final Results From the EPIC3 Program
11/09/2010

Can Chronic Hepatitis C Patients with
Genotypes 2 or 3 Benefit from Shorter Interferon Treatment?
10/26/2010


Week 4 Rapid Virological Response Predicts Sustained Response to Interferon-based Hepatitis C Treatment
9-03-2010

Pegylated Interferon plus Ribavirin Has High Sustained Response Rates in Children with Hepatitis C
8-31-2010

Asian Patients Respond as Well as Whites to Interferon-based Therapy for Chronic Hepatitis C
7-13-2010

Response at Week 8 Accurately Predicts Sustained Response to Pegylated Interferon plus Ribavirin for Hepatitis C
7-05-2010

Blood-boosting Adjuvant Therapies Can Improve Response to Interferon-based Treatment for Hepatitis C
6-25-2010

Sustained Virological Response at 12 Weeks Post-treatment May be as Good as 24 Weeks for Determining Interferon Cure
6-11-2010

Nitazoxanide Increases Response to Pegylated Interferon plus Ribavirin in Treatment-naive and Non-responder Hepatitis C Patients
5-28-2010

Pegylated Interferon plus Ribavirin Works as Well in HIV/HCV Coinfected Patients with Cirrhosis
5-28-2010

Controlled Release Interferon (Locteron) Every 2 Weeks Works as Well as Pegylated Interferon but with Fewer Side Effects
5-18-2010

HCV NS5A Inhibitor BMS-790052 Suppresses Viral Replication in Combination with Pegylated Interferon/ribavirin
4-30-2010

Closely Individualized Treatment with Pegylated Interferon plus Ribavirin Is Possible Based on Baseline Viral Load and Early Response
4-232010

Is One Type of Pegylated Interferon More Effective for Treating Chronic Hepatitis C?
2-12-2010

Influence of HCV Subtype and Quasispecies on Virological Response to Interferon-Based Therapy
1-12-2010

Management of Non-responders and Relapsers Treated with Pegylated Interferon plus Ribavirin for Chronic Hepatitis C
1-5-2010

Low-dose Pegylated Interferon Maintenance Therapy Does Not Reduce Clinical Outcomes despite Persistent HCV Suppression
1-5-2010

HCV Viral Load Decline during First 48 Hours of Pegylated Interferon plus Ribavirin in HCV Monoinfected and HCV/HIV Coinfected Patients
12/04/09

Hepatitis C Treatment Appears to Be Declining; People with Hard-to Treat Genotypes Are Half as Likely to Receive Therapy
12/01/09
Genotype 1 Chronic Hepatitis C Patients with Low Viral Load Can Achieve Sustained Response with 24 Weeks of Pegylated Interferon plus Ribavirin
11/17/09

Pegylated Interferon plus Ribavirin Can Effectively Treat both Hepatitis B and C In Dually Infected Patients
11/17/09

Reducing Ribavirin Dose Raises Relapse Risk for Chronic Hepatitis C Patients, but Pegylated Interferon May be Decreased after Week 12
10-13-2009

Advocates Urge Consideration of Hepatitis C Treatment for Active Injection Drug Users
8-14-2009

Pegasys and PegIntron for Chronic Hepatitis C Perform Similarly in IDEAL Study
7-28-2009

Detectable HCV RNA at Week 8 Is Best Predictor of Relapse in Genotype 1 Hepatitis C Patients Treated with Pegylated Interferon plus Ribavirin
6-23-2009


Effectiveness of Pegylated Interferon plus Ribavirin for Chronic Hepatitis C Patients with HCV Genotypes 5 or 6
6-19-2009


Reduced Dose and Duration of PegIntron plus Ribavirin Is Not as Effective as Standard Therapy for Genotype 2 and 3 Hepatitis C Patients
5-29-2009


IDEAL Study Shows that Greater Hemoglobin Decline during Treatment with Pegylated Interferon plus Ribavirin Is Associated with Better Response
5/22/09


FDA Approves Dose Adjustments of PegIntron and Rebetol for Certain Patients with Chronic Hepatitis C
5/15/09

Extended 72-week Treatment with Pegylated Interferon plus Ribavirin Did Not Improve Outcomes among Slow Responder Hepatitis C Patients
5/08/09

Pegylated Interferon alfa-2b (PegIntron) Maintenance Monotherapy May Reduce Esophageal Varices in Hepatitis C Patients with Cirrhosis
5/05/09


Adding Boceprevir to PegIntron/Ribavirin Significantly Improves Sustained Virological Response in Chronic Hepatitis C Patients
5/05/09


Early Treatment of Acute Hepatitis C with Pegylated Interferon Monotherapy Produces Better Results than Delayed Combination Therapy
5/05/09


Adding Telaprevir Improves Sustained Response to Pegylated Interferon plus Ribavirin in Genotype 1 Chronic Hepatitis C Patients (PROVE3)
5/05/09


Experimental HCV Protease Inhibitor SCH 900518, with or without Pegylated Interferon, Appears Safe and Exhibits Good Antiviral Activity
5/05/09


Reduced Dose and Duration of Peginterferon alfa-2b and Weight-Based Ribavirin in European and Asian Genotype 2 and 3 Chronic Hepatitis C Patients (REDD 2/3 Trial) Final Analysis
5/05/09


Individualized treatment duration with peginterferon alfa-2b and ribavirin for 24, 30 or 36 weeks in HCV genotype 1-infected patients with undetectable HCV-RNA early during therapy (INDIV-2 study)
5/05/09

Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C
5/05/09


HIV Positive and Negative Individuals with Acute or Early Chronic Hepatitis C Respond Well to 24 Weeks of Pegylated Interferon plus Ribavirin
4/10/09


Review Finds Albumin Interferon for Chronic Hepatitis C Is Effective and Well-tolerated; Phase 3 Results Show Non-inferiority to Pegylated Interferon
3/20/2009


FDA Approves New Indication for PegIntron plus Ribavirin for Certain Patients Who Failed Prior Hepatitis C Treatment
3/13/2009


FDA Approves New Indication for PegIntron plus Ribavirin for Certain Patients Who Failed Prior Hepatitis C Treatment
3/13/2009


Phase 1 OPTIMA Trial Finds Controlled-release Nitazoxanide Improves Response to Pegylated Interferon plus Ribavirin
2/27/2009


Extended Pegylated Interferon plus Ribavirin Therapy Improves Sustained Response Rate in Slow Responder Genotype 1b Hepatitis C Patients
2/03/2009

Adherence to Pegylated Interferon/ribavirin Therapy for Hepatitis C and Early Treatment Response
1/30/2009


Combination of Virus and Host Factors Predict Virological Response to Pegylated Interferon plus Ribavirin for Chronic Hepatitis C
1/27/2009


PegIntron plus Ribavirin Approved for Children with Chronic Hepatitis C
1/05/2009


Intron A + Rebetol
(interferon alfa-2b + ribavirin)

Articles on Intron A + Rebetol

Asian Patients Respond as Well as Whites to Interferon-based Therapy for Chronic Hepatitis C
7-13-2010

HCV Therapeutic Vaccine GI-5005 Improves Rate of Sustained Response to Interferon-based Therapy for Hepatitis C
4-30-2010

Interferon-based Therapy Less Effective for Hepatitis C Patients with Advanced Liver Fibrosis or Cirrhosis
4-9-2010

Can Some Genotype 1 Chronic Hepatitis C Patients Benefit from Shorter Interferon-based Treatment?
2/16/2010

Management of Depression During Hepatitis C Treatment with Interferon-based Therapy
1/29/2010

Influence of HCV Subtype and Quasispecies on Virological Response to Interferon-Based Therapy
1/12/2010

Sustained Response to Interferon-based Therapy Leads to Improved Quality of Life in Chronic Hepatitis C Patients
12/11/09

Hepatitis C Treatment Appears to Be Declining; People with Hard-to Treat Genotypes Are Half as Likely to Receive Therapy
12/01/09

Sustained Virological Response to Interferon-based Therapy Slows Progression of Liver Cirrhosis in Hepatitis C Patients
11/24/09

HCV Viral Load Decline during the First 24 Hours of Interferon-based Therapy Predicts Long-term Outcomes in HIV-HCV Coinfected Patients
9-18-2009

FDA Requires Updated Labeling for Interferon Alpha Products Due to Recently Identified Safety Issues
9-04-2009

Genetic Variation Helps Explain Differences in Response to Interferon-based Therapy for Hepatitis C
8-21-2009

Increases in ALT Late in the Course of Interferon-based Therapy for Chronic Hepatitis C Predicts Relapse
7-17-2009


Interferon-based Therapy Reduces or Reverses Liver Fibrosis over the Long-term in Chronic Hepatitis C Patients
7-07-2009


Early Bilirubin Elevation May Predict Severe Anemia during Interferon/ribavirin Treatment for Chronic Hepatitis C
7-07-2009


Older Genotype 3 Chronic Hepatitis C Patients Do Not Respond as Well to Interferon-based Therapy
6-16-2009


Vitamin B12 Levels May Help Predict Response to Interferon-based Therapy for Chronic Hepatitis C
6-5-2009


HCV Viral Load Decline at Day 2 of Interferon-based Therapy Predicts Sustained Response, Explains Poorer Outcomes in African-Americans
6-2-2009


Interferon-based Therapy for Hepatitis C Improves Fibrosis Even in Individuals without Virological Response
4/21/09


Sustained Response to Interferon-based Therapy Reduces Risk of Diabetes in Hepatitis C Patients
4/21/09


A Small Proportion of Hepatitis C Patients Develop Liver Cancer despite Sustained Response to Interferon-based Therapy
4/13/09


Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C
4/03/09


Cyclical Treatment Interruption in Patients Taking Interferon-based Therapy for Chronic Hepatitis C
2/10/2009


CD4 T-cell Responses to HCV during and after Interferon-based Therapy for Chronic Hepatitis C
12/05/2008


Therapies to Manage Insulin Resistance Improve Response to Interferon-based Therapy in Chronic Hepatitis C Patients
11/21/2008


Sexual Desire, Function, and Satisfaction in Men Undergoing Treatment with Interferon-based Therapy for Chronic Hepatitis C
11/14/2008

Roferon A + Ribavirin
(interferon alfa-2a + ribavirin)

Articles on Roferon A + Ribavirin

Asian Patients Respond as Well as Whites to Interferon-based Therapy for Chronic Hepatitis C
7-13-2010

Interferon-based Therapy Less Effective for Hepatitis C Patients with Advanced Liver Fibrosis or Cirrhosis
4-9-2010

Can Some Genotype 1 Chronic Hepatitis C Patients Benefit from Shorter Interferon-based Treatment?
2/16/2010

Management of Depression During Hepatitis C Treatment with Interferon-based Therapy
1/29/2010

Influence of HCV Subtype and Quasispecies on Virological Response to Interferon-Based Therapy
1/12/2010

Hepatitis C Treatment Appears to Be Declining; People with Hard-to Treat Genotypes Are Half as Likely to Receive Therapy
12/01/09

Sustained Virological Response to Interferon-based Therapy Slows Progression of Liver Cirrhosis in Hepatitis C Patients
11/24/09

HCV Viral Load Decline during the First 24 Hours of Interferon-based Therapy Predicts Long-term Outcomes in HIV-HCV Coinfected Patients
9-18-2009

FDA Requires Updated Labeling for Interferon Alpha Products Due to Recently Identified Safety Issues
9-04-2009

Increases in ALT Late in the Course of Interferon-based Therapy for Chronic Hepatitis C Predicts Relapse
7-17-2009

Interferon-based Therapy Reduces or Reverses Liver Fibrosis over the Long-term in Chronic Hepatitis C Patients
7-07-2009


Early Bilirubin Elevation May Predict Severe Anemia during Interferon/ribavirin Treatment for Chronic Hepatitis C
7-07-2009


Interferon-based Therapy for Hepatitis C Improves Fibrosis Even in Individuals without Virological Response
4/21/09


Sustained Response to Interferon-based Therapy Reduces Risk of Diabetes in Hepatitis C Patients
4/21/09


A Small Proportion of Hepatitis C Patients Develop Liver Cancer despite Sustained Response to Interferon-based Therapy
4/13/09


Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C
4/03/09

Infergen + Ribavirin
(Consensus Interferon + Ribavirin)

Infergen Prescribing Information


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 Google Custom Search
 
Experimental Treatments
Treatment Guidelines

HCV Articles by Topic

Cirrhosis
Fibrosis
Hepatocellular Carcinoma
Liver Transplantation
Liver Biopsy

Steatosis
Anemia
Children / Infants / Women
Drug Abuse
Experimental Treatments
FAQs About Hepatitis C
Genotypes
Insulin Resistance / Diabetes
Sustained Viral Response (SVR)
Tests for HCV
Vaccines for HCV